Assessing Inspire Medical Systems (INSP) Valuation After Prolonged Share Price Weakness

Event context and recent share performance Inspire Medical Systems (INSP) stock has drawn attention after an extended period of weak returns, including a 70.19% decline over the past year and a 47.71% decline year to date. Those moves leave the company valued at about US$1.58b, with shares closing at US$48.25. This has prompted investors to reassess how the obstructive sleep apnea specialist is currently being priced. See our latest analysis for Inspire Medical Systems. That 12% one day share price decline caps a weak run over the past year, with both short term share price returns and longer term total shareholder returns firmly negative. This suggests sentiment has cooled and investors are reassessing the risk profile. If you are looking beyond this sell off and want to see where capital is flowing in healthcare technologies, it could be useful to scan other sleep and treatment related plays in the medical space. One option is to use a focused healthcare AI stock screener such as 34 healthcare AI stocks. After such steep share price declines and a market value of about US$1.58b, the key question now is whether Inspire Medical Systems is trading below its underlying worth or if the stock already reflects expectations for any future growth. Most Popular Narrative: 39.2% Undervalued With Inspire Medical Systems last closing at $48.25 against a narrative fair value of $79.42, the current setup reflects a wide gap between that framework and the share price. The recent delay in transitioning centers to the Inspire V next-generation system, including slower onboarding, delayed SleepSync implementation, and the Medicare billing update, are transitory issues; as these barriers resolve (with Medicare billing now live and most centers expected to complete onboarding by end of Q3), procedure volumes and revenue growth are positioned to reaccelerate in 2026 as pent-up demand is realized. Read the complete narrative. Want to understand why a slower earnings path still underpins that higher fair value? The narrative leans on measured revenue growth, resilient margins and a premium earnings multiple years out. Result: Fair Value of $79.42 (UNDERVALUED) Have a read of the narrative in full and understand what's behind the forecasts. However, that higher fair value view still faces real tests, including a slower Inspire V rollout and potential shifts in reimbursement that could strain revenue and earnings assumptions. Find out about the key risks to this Inspire Medical Systems narrative. Next Steps Given that the sentiment here is mixed, it makes sense to move quickly and test the bullish and cautious points against the data yourself. To see what is currently driving optimism around the company, review its 3 key rewards. Looking for more investment ideas? If Inspire Medical Systems is on your radar, do not stop there; broaden your watchlist now so you are not late to the next opportunity. Zero in on potential value opportunities by scanning companies that currently screen as 48 high quality undervalued stocks. Strengthen your downside protection by focusing on businesses filtered through the 71 resilient stocks with low risk scores. Get ahead of the crowd by researching companies highlighted in the screener containing 25 high quality undiscovered gems. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.New: AI Stock Screener & AlertsOur new AI Stock Screener scans the market every day to uncover opportunities.• Dividend Powerhouses (3%+ Yield)• Undervalued Small Caps with Insider Buying• High growth Tech and AI CompaniesOr build your own from over 50 metrics.Explore Now for Free